ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, announced that Peter Ho, Ph.D., has joined the Company as Head of Business Development and Corporate Strategy.
“I am thrilled to have Peter join our executive team at this pivotal time as we advance our three Phase 2 programs in rare and acute inflammatory diseases,” said David Marek, Chief Executive Officer of ReAlta. “Peter’s expertise in business development and corporate strategy, which spans biopharmaceutical companies of all sizes and stages, will be a tremendous asset for ReAlta as we look to maximize opportunities for our platform.”
“ReAlta has key inflection points in the near future across the Company’s three lead clinical programs in hypoxic ischemic encephalopathy (HIE), acute graft-versus-host disease (aGvHD), and acute exacerbations of chronic obstructive pulmonary disease (AE-COPD), as well as a promising and unique platform to generate additional assets with the potential to address huge unmet needs in both acute and chronic inflammatory diseases,” said Dr. Ho. “I look forward to working with Dave and the rest of the ReAlta team to identify opportunities to create value for the company and, most importantly, for patients facing life-threatening diseases.”
Dr. Ho has more than 20 years of biopharmaceutical industry experience. Prior to joining ReAlta, he was Head of Cell Therapy Business Development at Ginkgo Bioworks. He has held senior business development roles at a variety of biotechnology companies, including Nektar Therapeutics, BeiGene, Iovance, and Allergan. Dr. Ho has also led negotiations to execute drug discovery collaborations and clinical development partnerships, as well as license agreements. Earlier in his career, he worked in early-stage drug company investments at D.E. Shaw, in finance as an equity research analyst covering major pharmaceutical companies, as well as in advertising and communications at Grey Healthcare Group. Dr. Ho has an MBA from the UCLA Anderson School of Management, a Ph.D. in biology from the University of California, San Diego, and undergraduate degrees in chemistry and biology from the University of California, Irvine.
Learn more here.